Nav: Home

Better prognosticating for dogs with mammary tumors

June 14, 2019

Mammary tumors in dogs are the equivalent of breast cancers in people, and, as in the human disease, the canine tumors can manifest in a variety of ways. Some are diagnosed early, others late, and they can be either slow growing or aggressive.

Yet current prognostic tools, which provide information about the tumor stage--how large or dispersed it is--and grade--how likely it is to grow quickly--don't always give veterinarians or owners clear picture of how a tumor is going to progress, and what treatments might be most appropriate.

A new "bio-scoring" system, devised by a team led by Karin Sorenmo, a veterinary oncologist at Penn's School of Veterinary Medicine, equips clinicians with a more reliable prognosticating method. The researchers shared their work in the journal Veterinary and Comparative Oncology.

"Mammary gland carcinomas are the most common tumors in intact dogs around the world," says Sorenmo. "Yet we still haven't made great progress in deciding which dogs are fine with just surgical treatment, which dogs might require chemotherapy, and which dogs might benefit from hormonal treatment. In testing this new approach, we found it helps identify the dogs that develop metastasis better than other methods. I'm very excited about it."

To develop and assess this new scoring method, Sorenmo relied on a unique dataset that emerged from Penn Vet's Shelter Canine Mammary Tumor Program. This initiative, spearheaded by Sorenmo, enables shelter dogs to receive treatment for their mammary tumors, then finds foster or permanent homes for each animal. Researchers such as Sorenmo and others benefit from studying the dogs, including how they respond to treatment.

The current work took data from 96 dogs treated through the program, as well as an additional 31 dogs treated in a similar fashion at the Norwegian University of Life Sciences. The records they used including the pets' disease stage, grade, treatments received, and outcome--specifically, the time to metastasis, or spread of their disease within the body.

The "golden rule" for determining treatment currently, Sorenmo says, is to look at tumor stage, from stage I when the tumor is localized and small, up to stage IV when it has spread to distant organs.

"That's fine for some tumors that tend to behave in a certain way," Sorenmo notes, "but with mammary tumors it can be such a diverse disease."

Dogs can have advanced stage disease but, if their tumor has a low grade--that is, it is not fast-growing--they may have a better outcome than a dog with a lower stage but a more advanced grade. In addition, a tumor's histology, or the molecular markers that characterize the cancer cells, can further influence its behavior and the eventual outcome of treatment.

"We really didn't have a system to pull all the data together," Sorenomo says.

Looking to human oncology, Sorenmo and colleagues decided to borrow the idea of a scoring method that has been used to categorize breast cancers. They pulled together three pieces of information to attempt to more accurately determine a dog's prognosis: stage, grade, and histological type.

Some interesting findings arose from the statistical analysis. "We found that if you had a grade 1 tumor, no matter how large it gets, the vast majority of the time it doesn't cause any trouble," she says.

Since a good number of the dogs in the study had experienced long delays in receiving care due to being abandoned or in shelters, and thus had larger tumors than one would expect to see in the pet populations, the researchers were able to detect this size-independent effect.

"It's the same thing with lymph node involvement," says Sorenmo. "Everyone thinks that is a sign that the cancer has already started to move, but again we found that with a grade 1 tumor it doesn't matter. Those dogs didn't develop distant metastasis."

Using the overall bio-score, the researchers were able to differentiate dogs at lower risk of developing metastasis from those at a higher risk. If a pet has a higher bio-score, Sorenmo says, then a veterinarian or an owner may want to consider more aggressive treatment options, including chemotherapy. Dogs with a lower bio-score, on the other hand, may do just as well with surgical intervention alone.

In future work, Sorenmo would like to build on these findings by isolating the effect of hormones on mammary tumor and disease progression. Since the standard of care for treating dogs in the program is to spay them, she notes that doing so may remove a source of hormones that could be contributing to the dogs' disease in many cases.

For now, she is glad to have developed a system that can be implemented easily and immediately into treatment planning decisions.

"I try not to publish on things that most practicing veterinarians are not going to be able to use, like fancy tests that they won't routinely order," Sorenmo says. "This is practical. You look at three different things, given them a number and add it up."
-end-
Karin Sorenmo is a professor of oncology in the University of Pennsylvania School of Veterinary Medicine.

Sorenmo's coauthors were Amy C. Durham, Michael C. Goldschmidt, and Darko Stefanovski of Penn Vet; Veronica Kristiansen of the Norwegian University of Life Sciences; and Laura Pena of Complutense University of Madrid.

The study was supported by the Penn Vet Shelter Canine Mammary Tumor Program, the Petco Foundation, and the Blue Buffalo Foundation.

University of Pennsylvania

Related Cancer Articles:

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.
Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.
Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Debbie Millman: Designing Our Lives
From prehistoric cave art to today's social media feeds, to design is to be human. This hour, designer Debbie Millman guides us through a world made and remade–and helps us design our own paths.
Now Playing: Science for the People

#574 State of the Heart
This week we focus on heart disease, heart failure, what blood pressure is and why it's bad when it's high. Host Rachelle Saunders talks with physician, clinical researcher, and writer Haider Warraich about his book "State of the Heart: Exploring the History, Science, and Future of Cardiac Disease" and the ails of our hearts.
Now Playing: Radiolab

Insomnia Line
Coronasomnia is a not-so-surprising side-effect of the global pandemic. More and more of us are having trouble falling asleep. We wanted to find a way to get inside that nighttime world, to see why people are awake and what they are thinking about. So what'd Radiolab decide to do?  Open up the phone lines and talk to you. We created an insomnia hotline and on this week's experimental episode, we stayed up all night, taking hundreds of calls, spilling secrets, and at long last, watching the sunrise peek through.   This episode was produced by Lulu Miller with Rachael Cusick, Tracie Hunte, Tobin Low, Sarah Qari, Molly Webster, Pat Walters, Shima Oliaee, and Jonny Moens. Want more Radiolab in your life? Sign up for our newsletter! We share our latest favorites: articles, tv shows, funny Youtube videos, chocolate chip cookie recipes, and more. Support Radiolab by becoming a member today at Radiolab.org/donate.